Evidence map›Paper›PMID 36009531›Full record

ArticleBiomedicines2022

Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.

Mohammad Hussein, Lauren Mueller, Peter P Issa, Muhib Haidari, Lily Trinh, Eman Toraih, Emad Kandil

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mohammad HusseinDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Lauren MuellerSchool of Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0002-6459-9839
Peter P IssaSchool of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0002-5248-3142
Muhib HaidariSchool of Medicine, Tulane University, New Orleans, LA 70112, USA.
Lily TrinhSchool of Medicine, Tulane University, New Orleans, LA 70112, USA.
Eman ToraihDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0001-9267-3787
Emad KandilDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Tulane University · USLouisiana State University Health Sciences Center New Orleans · USSuez Canal University · EG

Funding

American Thyroid Association THYROIDGRANT2021-0000000232Tulane University Tulane University Bridge Fund
6 · The paper itself

Abstract

Primary cancer survivors have a higher risk of developing second primary thyroid cancer (SPTC). Patients with SPTC who survived primary malignancies, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 18 Registry). A total of 33,551 cancer cases were enrolled in the final analysis. Individuals with a primary malignancy were at a significant 90% increased risk of developing SPTC (SIR = 1.90, 95%CI = 1.86−1.93, p < 0.05) compared to the general population. More than half (54.7%) of SPTC diagnoses were made in the first three years after primary cancer diagnosis, and the most aggressive presentations of SPTC occurred within the first year following malignancy. A latency trend analysis identified persistent high risk for development of SPTC after diagnosis of lymphoma, leukemia, soft tissue tumors, kidney, breast, and uterine cancer; elevated 10-year risk for most cancers such as salivary gland, melanoma, stomach, lung, colon, ovarian, pancreas, prostate, and bladder; and high 5-year risk after cancers such as larynx, oral, orbit, bone, small intestine, and liver. Our latency period model identifying risk according to each type of primary cancer may aid clinicians in identifying at-risk patients to be screened for thyroid cancer and guide them in developing a surveillance plan according to the latency period attributed to a patient’s primary cancer.

Indexed as

screeningsecond primary thyroid cancerSEERthyroid latency

Identifiers

PMID36009531
PMCPMC9406053
OpenAlexW4292291558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.